Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The minimally clinically important difference in generic utility-based measures.

Robert M Kaplan1

  • 1Department of Health Services, UCLA School of Public Health, PO Box 951772, Room 31-293C CHS, Los Angeles, California 90095-1772, USA. rmkaplan@ucla.edu

COPD
|December 2, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Provider Type Market Share for Treatment of Depression in a Large Commercially Insured Population.

Psychiatric services (Washington, D.C.)·2026
Same author

Employee preferences in health plan design: results from a national survey.

Health affairs scholar·2026
Same author

Does the relationship between health and behavior depend on changes in immune functioning?

Translational behavioral medicine·2026
Same author

Preferences for Shared Language for Health Equity Across the Political Spectrum.

JAMA network open·2026
Same author

Age-related differences in social ecosystems of physical activity in African American women.

Health psychology : official journal of the Division of Health Psychology, American Psychological Association·2026
Same author

The glymphatic system clears amyloid beta and tau from brain to plasma in humans.

Nature communications·2026
Same journal

Global, Regional, and National Burden of COPD Attributable to Secondhand Smoke from 1990 to 2021: Findings from the Global Burden of Disease Study 2021.

COPD·2026
Same journal

Upregulation of LncRNA MIR31HG in COPD Correlates with Disease Severity and Facilitates Inflammation via miR-342-3p.

COPD·2026
Same journal

Methodological Considerations in the Development of the AECOPD "Infection Score".

COPD·2026
Same journal

Barriers and Facilitators to Treatment Plan Adoption and Self-Management in People with Chronic Obstructive Pulmonary Disease (COPD): A Systematic Search and Narrative Synthesis.

COPD·2026
Same journal

Airway Mucus Occlusions in Ex-Smokers with and Without COPD.

COPD·2026
Same journal

Symptom Improvement with BDP/FF/G Fixed Triple Inhalation Powder in Moderate to Severe COPD Patients Uncontrolled with Dual Therapies: A Non-Interventional, Open-Label, Single-Arm, Prospective Study (RESPONSE Slovenia).

COPD·2026
See all related articles

Utility-based quality of life measures offer a reliable way to determine the minimally clinically important difference (MCID) for patients with Chronic Obstructive Pulmonary Disease (COPD). These measures provide interpretable results for rehabilitation and surgical outcomes.

Area of Science:

  • Health Outcomes Research
  • Quality of Life Measurement
  • Clinical Trial Analysis

Background:

  • Utility-based quality of life (QoL) measures quantify wellness on a scale from 0.00 (death) to 1.00 (optimum function).
  • Preference measurement studies define scale points, with 0.03 units being the smallest discernible difference between health states.
  • This 0.03 threshold is proposed as a reasonable minimally clinically important difference (MCID) for these measures.

Purpose of the Study:

  • To assess the utility of generic, utility-based QoL measures for establishing MCID.
  • To evaluate the interpretability and sensitivity of these measures in clinical contexts.

Main Methods:

  • Analysis of three published studies involving patients with Chronic Obstructive Pulmonary Disease (COPD).

Related Experiment Videos

  • Data from the Quality of Well-being Scale (QWB) before and after pulmonary rehabilitation were examined.
  • One study included a randomized comparison of lung volume reduction surgery versus maximal medical therapy, with 29-month follow-up.

    • Main Results:

    • Pulmonary rehabilitation demonstrated QWB changes exceeding the 0.03 MCID threshold in all three evaluations.
    • Lung volume reduction surgery showed QWB changes near the MCID at one year, increasing in subsequent years.
    • Norman's 0.50 standard deviation method indicated that rehabilitation and surgery outcomes at one year fell below the MCID.

    Conclusions:

    • Estimating MCID using different methods yields varying interpretations of QoL changes after COPD interventions.
    • The preference scaling system in utility-based QoL measures offers direct interpretability and addresses criticisms of other MCID methods.
    • Utility-based measures are sensitive to clinically meaningful benefits and valuable for policy analysis (e.g., quality-adjusted life years), supporting their increased use in COPD research.